Heterodox
Obesity is a risk factor for cancer, heart disease stroke and diabetes. Thus, drugs like semaglutides (Wegovy, Ozempic) don’t just reduce weight in the obese, they also reduce risk of cancer, heart disease, stroke and diabetes, which are huge health care burdens. It’s good to see that Medicare is finally coming to grips with this obvious fact:“On March 8, 2024, FDA approved Wegovy (semaglutide) to treat cardiovascular disease risks — heart attack,...
Read More »